Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Obeticholic acid (OCA) shows sustained effectiveness and safety in primary biliary cholangitis (PBC) patients over medium-to-long term follow-up. Biochemical response to OCA correlates with improved liver stiffness measurements, suggesting a potential impact on fibrosis progression.
Area Of Science
- Hepatology
- Pharmacology
- Clinical Medicine
Background
- Obeticholic acid (OCA) is used for primary biliary cholangitis (PBC) treatment.
- Real-world data on OCA's long-term effectiveness and safety are needed.
- Previous studies focused on short-term outcomes.
Purpose Of The Study
- To evaluate the real-world effectiveness and safety of OCA in a large patient cohort.
- To assess changes in liver stiffness measurement (LSM) over time with OCA treatment.
- To explore OCA's impact on fibrosis progression in PBC patients.
Main Methods
- The RECAPITULATE project analyzed data from 747 Italian PBC patients.
- Effectiveness was measured by biochemical response (POISE and normal range criteria).
- Safety was assessed via adverse events (pruritus) and discontinuation rates; LSM was analyzed over time.
Main Results
- Biochemical response rates (POISE and normal range) increased significantly over 42 months.
- Discontinuation occurred in 17% of patients, primarily due to pruritus.
- Biochemical responders showed a significant decrease in LSM, while non-responders showed an increase.
Conclusions
- OCA demonstrates sustained effectiveness and a favorable safety profile in PBC patients.
- Biochemical response to OCA is linked to improvements in liver stiffness, indicating a potential anti-fibrotic effect.
- These findings support OCA's role in managing PBC, especially in specific patient subgroups.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Detailed History: Understanding the patient's symptoms is critical. It includes inquiring about abdominal pain, weight loss, and digestive issues, which are common in chronic pancreatitis.
Physical Examination: This might reveal abdominal tenderness, jaundice, and signs of malnutrition,...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...